Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
News|Podcasts|December 23, 2024
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
Pharmacy Times attended the 2024 San Antonio Breast Cancer Symposium from December 10 to December 13.
Advertisement
This episode of Pharmacy Focus: Oncology Edition highlights key insights from the 2024 San Antonio Breast Cancer Symposium, covering new FDA-approved therapies, dose optimization strategies, and innovative prevention approaches in breast cancer care.
Advertisement
Related to this article
Long-term CASSIOPEIA Registry results show that daratumumab maintenance supports sustained minimal residual disease negativity in transplant-eligible patients with newly diagnosed multiple myeloma.
Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
IRAKLIA shows isatuximab OBI boosts comfort and satisfaction vs IV in multiple myeloma, enabling fast at-home dosing with strong completion.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tavapadon, First D1/D5 Agonist for Parkinson Disease
2
CagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
3
Engineered Stem Cell Therapy Reverses New-Onset T1D in Mice by Reprogramming T Cells
4
Why 5 Injectable Drugs Have Been in Shortage for More Than a Decade
5